13F filer · CIK 1559565
Sofinnova Management VIII, L.L.C.
Menlo Park, CA · filing since Q4 2016 · last filing Feb 14, 2018
Reported value
$183.2M
+$19.2M vs prior
Positions
8
New / sold out
0 / 0
Added / reduced
2 / 0
Turnover
0.0%
buys $50.2M · sells $0
Top-10 weight
100.0%
Biggest buys vs Q3 2017
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | NuCana plc | +4,000,000 | +600.0% | +$40.4M |
| Added | ObsEva SA | +1,000,000 | +26.7% | +$9.8M |
Biggest sells vs Q3 2017
No reduced or sold positions this quarter.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q4 2017
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | NuCana plcAMERICAN DEPOSITARY SHARES | 4,666,666 | $47.2M | 25.76% |
| 2 | ObsEva SACOMMON STOCK | 4,749,623 | $46.4M | 25.31% |
| 3 | Aclaris Therapeutics, Inc.COMMON STOCK | 1,539,480 | $38.0M | 20.72% |
| 4 | Spark Therapeutics, Inc.COMMON STOCK | 481,270 | $24.7M | 13.51% |
| 5 | Natera, Inc.COMMON STOCK | 1,550,280 | $13.9M | 7.61% |
| 6 | Auris Medical Holding AGCOMMON SHARES | 7,818,175 | $4.6M | 2.52% |
| 7 | Histogenics CorporationCOMMON STOCK | 2,077,040 | $4.3M | 2.32% |
| 8 | Synlogic, Inc.COMMON STOCK | 424,972 | $4.1M | 2.25% |